Johny Cena
The use of tissue culture and biotechnology in manufacturing coronary stents has shown potential in reducing late complications. The development of biodegradable stents that can be absorbed into the body has minimized the risks associated with long-term complications such as restenosis and thrombosis. Tissue engineering techniques have also enabled the production of stents that mimic the structure and function of the natural vessel, promoting tissue regeneration and reducing inflammation. The incorporation of drug-eluting systems in stents has improved the efficacy of drug delivery to the targeted site, leading to reduced complications. These innovative technologies hold great promise for improving the outcomes of patients with coronary artery disease.